Study Comparing Reduced-Dose Apixaban and Rivaroxaban Versus Standard Low-Molecular-Weight Heparin for Preventing Blood Clots in Patients with Hematologic Cancers

What this Trial Is About

This research aims to evaluate the safety and effectiveness of reduced-dose direct oral anticoagulants DOACs, specifically apixaban and rivaroxaban, compared with standard low-molecular-weight heparin LMWH in preventing venous thromboembolism VTE in patients with hematologic malignancies such as multiple myeloma and lymphoma. The study addresses the challenge of thromboprophylaxis in this high-risk population, where current daily injections of LMWH may be burdensome and affect treatment adherence. The trial is prospective, randomized, and open-label, focusing on improved and patient-friendly prevention methods. Participants will be randomly assigned to one of three groups one receiving apixaban 2.5 mg orally twice daily, another receiving rivaroxaban 10 mg orally once daily, and the third receiving standard-dose LMWH via subcutaneous injection once daily. Each treatment will continue for at least six months. The study compares these regimens to assess their impact on VTE occurrence and bleeding risks, with a follow-up period of six months after treatment initiation. During the study, participants will be monitored for the incidence of venous thromboembolism, major and clinically relevant non-major bleeding events, overall survival, and adherence to the prescribed treatment over six months. Researchers will use standard clinical definitions and criteria to evaluate these outcomes. The trial includes regular assessments to ensure safety and collect data on any adverse events, aiming to provide high-quality evidence that could influence future thromboprophylaxis practices in patients with blood cancers.

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies